Lowering the Risk of Gout: Another Benefits From Use of SGLT2 Inhibitors

Journal of Diabetes Investigation - Australia
doi 10.1111/jdi.13254
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

SGLT2 Inhibitors

2020English

Gout Prevalence and Predictors of Urate-Lowering Therapy Use: Results From a Population-Based Study

Arthritis Research & Therapy
2018English

SGLT2 Inhibitors: Mind the Gap

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2016English

Correction To: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence Into Practice

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Risk of Amputations Associated With SGLT2 Inhibitors Compared to DPP-4 Inhibitors: A Propensity-Matched Cohort Study

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Class Effects of SGLT2 Inhibitors on Cardiorenal Outcomes

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2019English

SGLT2 Inhibitors for Primary Prevention of Cardiovascular Events

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Lipid Lowering: Another Method of Reducing Blood Pressure?

Journal of Human Hypertension
Internal Medicine
2002English

Is Cancer Incidence Modified by SGLT2 Inhibitors?

Diabetes Mellitus
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy